Breaks Categories: Stock Spotlights

FridayJul 10, 2020 1:50 pm

BioMedNewsBreaks – Vivos Therapeutics Inc.’s Innovative System Leverages Multidisciplinary Protocol in OSA Treatment

Vivos Therapeutics’ proprietary Vivos System(R) leverages a multidisciplinary treatment protocol comprised of comfortable oral devices and other therapies as needed. Over the course of treatment, typically ranging from 18 to 24 months, most patients experience an increased and enhanced upper airway with the purpose of reducing tissue obstructions causing obstructive sleep apnea (“OSA”). A recent article discussing this reads, “Vivos Therapeutics Inc. offers a new and superior alternative for treating obstructive sleep apnea, and the company believes its technology represents the most important breakthrough in OSA treatment since Continuous Positive Airway Pressure (‘CPAP’), which involves the use of special face…

Continue Reading

FridayJun 19, 2020 1:46 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. Develops Potential, Nonsurgical Solution for Obstructive Sleep Apnea

Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), has developed a groundbreaking remedy that holds the potential to be a possible solution for the life-threatening condition. A recent article further discussing the company reads, “This innovative medical device technology company has created and patented a novel system to combat OSA caused by deficiencies and other tissue anomalies in craniofacial anatomy development — the root cause behind 98% of OSA cases. The Vivos System requires no surgery but is a multidisciplinary treatment protocol that consists of comfortable and customized oral devices.  Over the typical 18-to-24-month…

Continue Reading

WednesdayJun 10, 2020 12:53 pm

BioMedNewsBreaks – Why Vivos Therapeutics Inc. Is ‘One to Watch’

Vivos Therapeutics, an emerging global leader in the treatment of obstructive sleep apnea (“OSA”), is on a mission to eliminate OSA using its revolutionary Vivos System(R), a clinical breakthrough in the treatment of sleep apnea caused by craniofacial anatomy development. An article discussing the company reads, “Designed to promote correct growth and development of the hard and soft tissues surrounding and compromising the oral cavity, nasal cavity, upper and lower jaws, and other tissues that comprise and shape the human airway. The system uses Pneumopedics(R), the natural process induced by Vivos biomimetic technology to widen and expand the patient’s airway,…

Continue Reading

MondayJun 01, 2020 2:09 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Applies Unique Database to Improve Cancer Outcomes

Predictive Oncology (NASDAQ: POAI), through its Helomics subsidiary, is leveraging its proprietary database of more than 150,000 tumor genomic and drug response profiles to improve cancer outcomes. An article discussing the company reads, “With a mission to improve the standard of care for cancer patients, Helomics’ TruTumor(TM) platform harnesses the power of the patient’s own living tumor to address challenges oncologists often face when assessing patients and individualizing treatments. The clinically validated (in ovarian cancer) cell-based functional platform is in use today and profiles patient tumors, identifying key biomarkers and how the tumor responds to drugs and helps the oncologist…

Continue Reading

FridayMay 29, 2020 1:10 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Helomics Subsidiary Holds Unique Cancerous Tumor Inventory

Predictive Oncology (NASDAQ: POAI) CEO Dr. Carl Schwartz recently referred to the company’s Helomics subsidiary as a “major asset” during an exclusive BMW interview with Stuart Smith (http://nnw.fm/54qVZ). An article discussing the interview reads, “During the interview, Schwartz pointed out that Helomics’ collection of more than 150,000 cancer tumors is the largest inventory of its kind in the world and that the impressive collection ‘was amassed over the last two decades by physicians sending in cancerous tumors to be tested with the known therapies of the time. The results of these tests were in turn sent back to the referring physicians…

Continue Reading

FridayMay 22, 2020 2:26 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Exchanges $2.1M Promissory Note for Common Stock

Predictive Oncology (NASDAQ: POAI) recently entered an agreement with POAI CEO Dr. Carl Schwartz to exchange a $2.1 million promissory note for newly issued equity (http://nnw.fm/Y1UeQ). An article discussing the company reads, “‘This agreement enables the company to strengthen its balance sheet and simplify its capital structure at a critical juncture in our quest to commercialize our highly valuable database of cancer tumors for the advancement of predictive medicine,’ Schwartz said in a news release. ‘At the same time, it reinforces my commitment and demonstrates my belief in our ability to emerge as a leader in the application of artificial intelligence…

Continue Reading

ThursdayApr 30, 2020 2:40 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing CancerQuest2020 Initiative

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently reported that its Helomics subsidiary is making headway toward its goal of developing an AI-driven predictive model of ovarian cancer (http://nnw.fm/W2TJb). An article discussing the company reads, “This achievement will be a key milestone for the company’s CancerQuest2020 initiative. . . . CancerQuest2020 is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome leveraging Helomics’ huge knowledge base of tumor profiles. Predictive models embody the knowledge from these profiles to create a ‘computational…

Continue Reading

FridayApr 17, 2020 12:15 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Securities Purchase Agreement to Raise $3.5 Million

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently entered into a securities purchase agreement with certain accredited investors to purchase shares of common stock (http://nnw.fm/r6SCU). An article discussing the company reads, “The company explained that it has entered into a securities purchase agreement with certain accredited investors to raise $3.5 million through the issuance of up to 1,650,165 shares of common stock (or common stock equivalents) and accompanying warrants to purchase an aggregate of up to 3,300,330 shares of common stock at $2.121 per share of common stock and…

Continue Reading

TuesdayApr 07, 2020 3:07 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches AI Vaccine, Drug-Development Platform Targeting Coronaviruses, Acute Respiratory Syndromes

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced the launch of a new AI vaccine and drug development platform targeting coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS and SARS). An article discussing the company reads, “Through an interim operating agreement with Soluble Therapeutics, POAI believes the extensive experience utilizing artificial intelligence in its Helomics division to better understand and battle cancer will prove invaluable in the quest for solutions to the current global health crisis. Combining the HSC(TM) Technology with POAI’s predictive modeling platform is expected to…

Continue Reading

WednesdayFeb 26, 2020 12:21 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Employs Unique Cancer-Research Approach

Predictive Oncology’s (NASDAQ: POAI) flagship subsidiary TumorGenesis is making strides in the identification and separation of cancer-related biomarkers in an effort to quicken the development of new, effective therapeutics. TumorGenesis is currently utilizing a new trend in cancer research that leverages patient-derived xenografts (“PDx”). A recent article discussing the company reads, “Science has shifted to these much more accurate PDx models: A cancer patient’s tumor cells are implanted into an alternate environment to simulate the natural development of the tumor. By ‘fooling the tumor’ with an imitative environment, new drugs are able to be tested and potentially approved — all…

Continue Reading